drugset / Trial / NCT01480323
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
NaSingle-groupOpen-labelTreatment
Summary
The current clinical trial shall clarify a synergistic effect with regards to efficiency by the combination of intratumoral injection of interleukin-2 (IL-2) and the intra-venous application of ipilimumab.
Timeline
- Start
- 2012-02
- Primary completion
- 2014-09
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 9e+06 iu | Other |